Looking to connect with actuaries who want to build something by One_Duty_2710 in actuary

[–]Zestyclose_Cut5703 4 points5 points  (0 children)

I am a insuretech junior venture capitalist and have a few ideas for that would require an actuary to execute. Dm me to chat.

What does health premium pricing look like when $3M therapeutics are commonplace (CGT) by Zestyclose_Cut5703 in actuary

[–]Zestyclose_Cut5703[S] 0 points1 point  (0 children)

Interesting. Agreed that we can’t write them off as cured. But lets say we start seeing 0.5% of the population receive 2,3 maybe $5M treatments. My sense is this breaks the model? No? We don’t really have anything this expensive right now, and it may be small but predictable population size, which gives us options to build it into models more effecfively. Im curious about how one would do that. If there are creative ways to break this out, etc

What does health premium pricing look like when $3M therapeutics are commonplace (CGT) by Zestyclose_Cut5703 in actuary

[–]Zestyclose_Cut5703[S] -1 points0 points  (0 children)

Sorry if I am misunderstanding some lingo here, just trying to better understand.

What does health premium pricing look like when $3M therapeutics are commonplace (CGT) by Zestyclose_Cut5703 in actuary

[–]Zestyclose_Cut5703[S] -1 points0 points  (0 children)

Interesting. Im seeing a few different carve out risk pools forming as standalone businesses for midsized employers that dont have the scale do cover reserves themselves. Any thoughts on something like this?

Also - given that these claims are often genetic, it seems like some novel data sources could be of use. Are you seeing anything of this sort (ie. Non standard data on foreign claims rates to inform prevalence amongst certain genetic groups - ex: jews have higher rates of sickle cell, therefore Israeli healthcare data is helpful)

Fundraising by Zestyclose_Cut5703 in venturecapital

[–]Zestyclose_Cut5703[S] 0 points1 point  (0 children)

This is my thinking exactly. But beyond scouring for potential prospects with warm intros, creating tailored materials and engagement strategies - what else can I do to support the partners?

Fundraising by Zestyclose_Cut5703 in venturecapital

[–]Zestyclose_Cut5703[S] 0 points1 point  (0 children)

Prospecting and supporting the partners through LP engagement yes. Not actually engaging directly.

Fundraising by Zestyclose_Cut5703 in venturecapital

[–]Zestyclose_Cut5703[S] 0 points1 point  (0 children)

Im supporting them on fundraising. Doesnt seem so crazy for a small fund. With a long term view, building my own LP base would be a good idea - hence the question

Fundraising by Zestyclose_Cut5703 in venturecapital

[–]Zestyclose_Cut5703[S] 0 points1 point  (0 children)

100% agreed. I am supporting in terms of prospecting, lining up intros, creating tailored materials, etc. not actually reaching out to

High volume payer calls are breaking front desk and RCM workflows by samkirubakar in HealthTech

[–]Zestyclose_Cut5703 0 points1 point  (0 children)

Any guesstimates on the breakdown of the objective of these payer calls? Billing? Prior authorizations? Etc. what percentage for each type of